Specialized AI agents combined with precise human-in-the-loop control points create accurate, high-quality regulatory documents up to 94% faster

SAN FRANCISCO, Oct. 7, 2025 — Peer AI, a leading agentic AI platform for life sciences regulatory documentation, today announced $12.1 million in total funding, led by Flare Capital Partners and SignalFire. Other investors included Greycroft, Atria, Alumni Ventures, Gaingels, and Mana Ventures, along with strategic angel investors from across the life sciences, healthcare, and technology industries.

Generating documentation for regulatory approval remains a critical drug development bottleneck. New drugs require over 200,000 pages spanning more than 1,500 unique documents. Manual and fragmented processes lead to missing data and discrepancies, often stalling approvals. Nearly one-third of FDA submissions have quality issues, and regulators reject almost 75% of applications, causing delays of 435 days.

The Peer AI platform deploys purpose-built, domain-specific AI agents combined with an intuitive AI-powered user interface that allows medical writers to apply their subject matter expertise at critical control points during documentation workflows. Top 20 pharmas and emerging biotechs are saving thousands of hours and improving quality of regulatory documents across pre-clinical, clinical, regulatory affairs, and chemistry, manufacturing, and controls (CMC) with Peer AI.

Customers are accelerating drafting times by 55–94%, cutting costs, and improving consistency and accuracy, while maintaining regulatory compliance. Medical writing teams have reduced clinical study report (CSR) drafting time from 40 to 17 working days and cut protocol turnaround from 6-8 weeks to just one week. Daily active use has grown 3X in the first three quarters of 2025, while overall platform volume has increased 6X, demonstrating strong adoption.

“Our vision is to create an intelligent regulatory workflow that connects documentation, data, and decision-making to speed drug approvals,” said Anita Modi, CEO and co-founder of Peer AI. “Documentation drives every step of the drug development process. We’re putting agentic AI in the hands of expert medical writers to create documents faster, improve quality, and, ultimately, accelerate treatments to patients.”

Agentic AI addresses regulatory documentation challenges

Peer AI uniquely combines agentic AI automation with strategic, easy to use human control points to scale AI-powered regulatory documentation efficiently and with the highest level of integrity. Purpose-built medical writing agents support experts in multi-step document creation, generating documents such as protocols, CSRs, investigational new drug (IND) applications, investigator’s brochures (IBs), and plain language summaries. Data source agents extract information from complex sources and ensure database integration. Authoring agents create accurate drafts aligned with regulatory guidelines, style agents ensure compliant formatting, and post-processing agents perform final validation checks.

With an intuitive user experience, experts can verify, validate, and quality control content throughout documentation workflows. A peer-led deployment model provides an expert team of medical writers to lead training, onboarding, and change management to help customers achieve the quickest time to value.

Strong market opportunity and validation

Today’s news signals a significant investment in an important market – which is estimated to be $15 billion – to make regulatory documentation more efficient. The funding will accelerate product development and commercial expansion as Peer AI scales to meet growing market demand. Founded by industry veterans with decades of experience in AI and life sciences, Peer AI is speeding timelines while ensuring accuracy and consistency across thousands of interconnected pages and documents.

“We see enormous opportunity in GenAI-based tools to unlock value in drug discovery and clinical development processes, including automating the end-to-end process of regulatory documentation,” said Ian Chiang, partner at Flare Capital Partners. “Peer AI’s distinctive approach and specialized agentic AI platform are shaped by in-house medical writer expertise. They’re already demonstrating strong early client engagement and poised to become a category-defining platform.”

“The Peer AI team’s deep expertise across life sciences and AI uniquely positions them to drive greater efficiency in the entire drug development workflow,” said Sooah Cho, partner at SignalFire. “They’re establishing the foundational regulatory backbone for life sciences to transform a historically fragmented, manual process with a unified agentic platform and intuitive user experience that brings experts in the loop at the right times.”

Peer AI has attracted leading advisors, including Ariel Katz, CEO and co-founder of H1, a data, analytics, and AI platform connecting the world to the right doctors, Brian Longo, veteran life sciences advisor and former executive at Veeva Systems, and Hanlin Tang, co-founder of MosaicML and currently the CTO for Neural Networks at Databricks.

The Peer AI agentic platform is available today. For more information, meet the Peer AI team at upcoming events, including RAPS Convergence, AMWA Medical Writing & Communications Conference, Clinical Trial Innovation Summit, SyncUP Summit , and CNS Summit to learn more and see a solution demo.

About Peer AI
Peer AI transforms regulatory documentation for life sciences companies through specialized AI agents that reduce drafting time. The agentic AI platform automates document creation across protocols, clinical study reports (CSR), narratives, investigational new drug (IND) applications, investigator’s brochures (IBs), and plain language summaries, while medical writers maintain oversight and control. Peer AI serves pharmaceutical, biotech, and CRO organizations worldwide. The company is backed by top investors and led by industry veterans with decades of experience in AI and life sciences. For more information, visit getpeer.ai.

About Flare Capital Partners

Flare Capital Partners is the leading healthcare technology venture capital firm advancing innovation-driven companies to improve positive health outcomes, broaden care access, and lower healthcare costs. We partner with exceptional founders solving healthcare’s hardest challenges, supporting each with our deep sector expertise, unparalleled industry resources, and proven access to commercial opportunities. Our team of established investors and senior operating executives has invested in 70+ companies and has nearly $1 billion in assets under management. To learn more about Flare Capital Partners, please visit flarecapital.com or follow us on LinkedIn, YouTube, or Spotify.

About SignalFire

SignalFire is the first AI-native VC firm built like a technology company to better serve the needs of founders as they build and scale their startups. With approximately $3B in assets under management, SignalFire invests in applied AI companies from pre-seed to Series B in key sectors, including Health & PharmaTech, cybersecurity, infrastructure, consumer, and other enterprise verticals.

The firm’s Beacon AI platform tracks over 650M employees and 80M organizations, giving the firm an unmatched data advantage in identifying and supporting world-class startups. Its sector-focused investors, XIRs from leading Health & PharmaTech unicorns, and a dedicated team of seasoned operators drive SignalFire at startup speed. They provide support across a company’s full lifecycle through data and resources tailored by growth stage, plus a diverse ecosystem of partners and customers. Notable investments include Grow Therapy, Ro, EvenUp, Frame.io, Grammarly, and Stampli.

Learn more at www.signalfire.com.

SOURCE Peer AI

Company Welcomes Dr. Chuck Mattera, former Chair and CEO of Coherent Corp as new Chairman

ALEXANDRIA, Va., Oct. 7, 2025 — HyperSpectral, the world’s first AI-powered spectral intelligence company, today announced the close of a $7M Series A-2 capital raise. The round will fuel accelerated development, expand partnerships, and position the company for a Series B round in 2026.

The financing was co-led by RRE Ventures and Kibo Ventures, with continued support from existing investors. New investors include Avalanche Thinking, whose Chairman and CEO, Dr. Vincent D. (Chuck) Mattera, former Chair and CEO of Coherent Corp, joins the HyperSpectral Board as Chairman. His appointment expands the company’s leadership network in photonics and industrial manufacturing, and his governance experience will reinforce the company’s readiness to scale ahead of its next financing round.

Since emerging from stealth mode in 2024, HyperSpectral has built significant momentum. In the past 12 months, its SpecAI™ platform was recognized as a Gartner Emerging Tech Innovator in Computer Vision Applications, named a 2025 R&D 100 Finalist, and honored with the coveted SPIE Prism Award. The company’s co-founders, CEO Matt Theurer and COO Lauren Stack, were honored by Washingtonian Magazine as 2025 “Tech Titans of the Year”.

“This round underscores investor conviction in our progress and potential,” said CEO Matt Theurer. “We are aiming to scale rapidly into the broad biotech, industrial, and defense markets and are excited to have Chuck Mattera join our Board. Chuck’s leadership and experience will be instrumental as we penetrate these markets in the U.S. and expand globally. In its initial deployments, HyperSpectral’s platform combines chemical physics and materials-science-based spectroscopy with advanced AI algorithms trained on proprietary data sets, enabling the rapid, non-invasive detection of bacteriological pathogens in minutes and without specialized lab preparation. This results in immediate breakthroughs in lower costs, faster cycle times, higher quality and better reliability,” said Theurer.

The $7M raise will provide resources to develop HyperSpectral’s technology platform further ahead of commercial scaling and solidify its leadership position with key customers and partners.

“Spectral Intelligence can change the way industries organize to leverage AI to help make decisions and control processes by providing data instantly, with differentiated advantages including reliability and scale,” said Dr. Chuck Mattera. “HyperSpectral has the vision, team, and technology to lead this transformation, and I am pleased to have been selected to join the Board and for Avalanche Thinking to support the company’s exciting growth aspirations.”

About HyperSpectral
Based in Alexandria, VA, HyperSpectral combines physics-based spectral data and advanced AI to deliver rapid, reliable answers in MedTech, food safety, and defense—enabling confident decisions when and where they matter most. For more information, visit https://www.hyperspectral.ai.

SOURCE HyperSpectral

Funding round led by Healthy.Capital and Nina Capital, with participation from Jeroen Tas and Harm-Jan Wessels

AMSTERDAM, Oct. 7, 2025 — Datamonk, the agentic AI-powered platform automating medical imaging data migrations, today announced it has raised $1.9 million in pre-seed funding to address one of healthcare IT’s biggest challenges: moving and cleaning decades of medical imaging data. The round was led by Healthy.Capital and Nina Capital, with participation from notable angel investors including Jeroen Tas, former Chief Innovation & Strategy Officer at Philips, and Harm-Jan Wessels, founder of Applicare (acquired by GE), Forcare (acquired by Philips), and Healthsage AI. The total also includes earlier support from Antler and Rabobank. The funding will support platform development, the advancement of AI capabilities, and team growth.

Hospitals and imaging providers hold decades of X-rays, CT scans, and MRIs in Picture Archiving and Communication Systems (PACS). They want to modernize, consolidate, and enable AI, but consultant-led migrations of millions of studies are slow and expensive, often taking a year or more to complete.

Datamonk uses agentic AI to automate PACS migrations while improving data quality. Its software agents detect and fix metadata issues, standardize study naming, and validate data integrity during the migration process. This enables hospitals to go live five to ten times faster and avoid much of the manual effort and cost of traditional consultant-led projects.

“Clean and connected data is the foundation for modern healthcare, from everyday clinical decisions to the deployment of new AI applications,” said Jaap Gielink, CEO and co-founder of Datamonk. “We don’t just move imaging data, we clean it and make it usable so hospitals can trust it is ready for clinical workflows, research, and innovation.”

“Getting access to integrated diagnostic data and insights is critical for healthcare providers, but imaging data migrations to the cloud have been a major showstopper. The Datamonk team brings a rare mix of healthcare, data, and AI expertise to solve this problem at scale,” said Jeroen Tas, former Chief Innovation & Strategy Officer at Philips.

“Imaging data is one of the most technically demanding areas of healthcare IT, given its scale and complexity. Datamonk’s use of agentic AI offers a scalable way to standardize and migrate data, creating the foundation for interoperability and future innovation,” said Marta G. Zanchi, founder and Managing Partner at Nina Capital.

“Datamonk is solving a problem for every hospital and vendor. Datamonk’s platform will help keep radiology affordable and accessible. We are excited to back the team in their mission to power healthcare with clean, connected data,” said Douwe Jippes, co-founder and Managing Partner at Healthy.Capital.

Datamonk was founded by Jaap Gielink (serial entrepreneur), Jai Bhatia (co-founder of Viewics Inc., a healthcare analytics platform acquired by Roche Diagnostics), and Matthew Condron (former CTO of leading healthcare data migration consultancy DesAcc). Datamonk’s growing team combines deep expertise in healthcare data, cloud technologies, and AI to build the data layer for modern healthcare.

About Datamonk

Founded in 2024 in the Netherlands, Datamonk builds the data layer for modern healthcare. Its platform uses agentic AI technology to automate PACS and VNA migrations, fix data quality issues, and help hospitals prepare imaging data for clinical use, research, and AI applications. Learn more at www.datamonk.ai.

About Healthy.Capital

At Healthy.Capital, we believe the future of healthcare starts with a digital revolution. We invest in startups that develop technological and digital solutions that reduce the demand for care, increase the productivity of healthcare professionals, and lower healthcare costs. In doing so, we contribute to a sustainable healthcare system for the future.

About Nina Capital

Nina Capital is an international, specialized venture capital firm investing in healthcare transformation powered by information technology and led by need-driven founders. Focused on pre-seed and seed-stage investments and guided by deep industry experience, Nina Capital supports health technology solutions that drive lasting healthcare impact. Nina Capital’s diverse, multinational, and multidisciplinary team is led by former healthcare technology founders and operators and combines expertise from numerous healthcare and technology sectors. Since 2019, Nina Capital has invested in 50 companies across nearly 20 countries, touching the lives of over 15 million people through healthcare technology innovations.

Media Contact:
Concetta Rasiarmos
Amendola for Datamonk
(630) 740-3152
[email protected]

SOURCE Datamonk

SANTA CRUZ, Calif., Oct. 6, 2025 — GAIM.FUN, an innovative AI-powered platform transforming how virtual worlds and games are built, today announced the successful completion of its Seed funding round. This round attracted a distinguished group of investors specializing in AI, gaming, and Web3, including Griffin Gaming Partners, Bitkraft Ventures, Benchmark, 1Up Ventures, Playground Global, Norwest Venture Partners, and Hiro Capital, signaling strong market confidence in GAIM.FUN’s pioneering vision.

GAIM.FUN empowers creators by enabling them to turn a single sentence into a fully explorable, interactive 3D environment within minutes. Its cutting-edge AI engine generates modular, editable assets seamlessly integrated with physics properties, dynamic narratives, and intelligent NPC behaviors. Compatible with Unity and Unreal engines, GAIM.FUN dramatically accelerates development pipelines for indie developers, small studios, educators, and UGC creators alike.

The platform’s unique approach combines generative world models with a user-friendly editor, eliminating traditional barriers in 3D content production. With GAIM.FUN, users can automatically generate branching storylines, intelligent quest logic, and deeply simulated environments—all customizable to fit any creative vision.

Proceeds from the seed round will propel further AI advancements, expand the engineering and creative teams, and amplify global marketing to grow a vibrant user ecosystem. GAIM.FUN is positioned to lead the future of immersive virtual experience creation.

About GAIM.FUN
Founded to empower creators through AI, GAIM.FUN turns natural language prompts into dynamic, interactive 3D worlds ready for game engines. The platform’s modular assets, integrated physics, and adaptive narratives enable rapid prototyping and production, making it a hub for modern digital storytelling.

SOURCE GAIM FUN LIMITED

Buckhannon, West Virginia, to receive multi-year investment through the company’s THRIVE program

SEATTLE, Oct. 6, 2025 — Weyerhaeuser Company (NYSE: WY) today announced a commitment to invest $1 million in Buckhannon, West Virginia, through the company’s THRIVE program. The investment will be made over the next several years with input from local elected officials, business leaders, nonprofits, employees and other community partners. Weyerhaeuser launched THRIVE in 2023 to provide targeted assistance to five of its rural operating communities; Buckhannon is the third community to be selected for the program.

“Rural operating communities like Buckhannon are so important to the success of our business and to the greater health of the forest products industry,” says Devin W. Stockfish, president and chief executive officer. “We want to make sure these communities remain great places to live, work and do business for years to come, and are looking forward to growing the positive impact of our THRIVE program as we expand it in Buckhannon and the surrounding area.”

Weyerhaeuser has operated an engineered wood products plant in Buckhannon, a community of about 5,300 in north-central West Virginia, for more than 25 years. The facility consistently ranks among the company’s top-performing sites for safety and manufacturing reliability. Weyerhaeuser also operates an oriented strand board mill in nearby Sutton, West Virginia, and sustainably manages more than 250,000 acres of timberlands across the state.

“We are excited and grateful to be selected as Weyerhaeuser’s next THRIVE community,” says Robbie Skinner, mayor of Buckhannon. “This investment is a clear signal of Weyerhaeuser’s commitment to Buckhannon, and we look forward to partnering with company leaders and the people of this great community to build a stronger and better future together.”

Weyerhaeuser’s THRIVE program is a key pillar of the company’s broader 3 by 30 Sustainability Ambition around rural communities and goes far beyond the financial investment. In selected communities, Weyerhaeuser leaders engage deeply with local stakeholders to identify and prioritize the challenges to be addressed through long-term collaboration, investment and advocacy. Potential opportunities in Buckhannon include youth education and workforce development.

“Every THRIVE community has different needs and priorities,” says Nancy Thompson, senior director of Advocacy and Philanthropy. “We’re looking forward to hearing directly from the Buckhannon community and working with the people and organizations there to support projects and community improvements that make a real and lasting impact.”

Zwolle, La., and the northwest Louisiana region was named the first THRIVE community in November 2023. Raymond, Wash., was selected for the program last year. The two remaining THRIVE communities — each of which will also receive a $1 million investment — will be announced as they are selected, starting in 2026. Selected communities represent areas where Weyerhaeuser has a significant presence and a history of employee and leadership engagement; where there are opportunities to take advantage of external resources, such as federal or state infrastructure grants, to strengthen advocacy efforts; and where Weyerhaeuser can partner with other employers, nonprofits and community leaders to amplify efforts and impact on the ground.

ABOUT WEYERHAEUSER
Weyerhaeuser Company, one of the world’s largest private owners of timberlands, began operations in 1900 and today owns or controls approximately 10.4 million acres of timberlands in the U.S., as well as additional public timberlands managed under long-term licenses in Canada. Weyerhaeuser has been a global leader in sustainability for more than a century and manages 100 percent of its timberlands on a fully sustainable basis in compliance with internationally recognized sustainable forestry standards. Weyerhaeuser is also one of the largest manufacturers of wood products in North America and operates additional business lines around product distribution, climate solutions, real estate, energy and natural resources, among others. In 2024, the company generated $7.1 billion in net sales and employed approximately 9,400 people who serve customers worldwide. Operated as a real estate investment trust, Weyerhaeuser’s common stock trades on the New York Stock Exchange under the symbol WY. Learn more at www.weyerhaeuser.com.

For more information contact:
Analysts – Andy Taylor, 206-539-3907
Media – Nancy Thompson, 919-861-0342

SOURCE Weyerhaeuser Company

A Total of $1.7 Million Raised in Q3 2025

TAMPA, Fla., Oct. 6, 2025 — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), an independent national Third-Party Administration (“TPA”) company today announced a private placement for the purchase and sale of 147,058 shares of common stock to HillCour Investment Fund, LLC (“HillCour”), an entity controlled by the Company’s Chief Executive Officer, Damien Lamendola, at a price of $1.36 per share for aggregate gross proceeds of approximately $200,000. The Company intends to use the net proceeds from the offering for general corporate purposes, including accelerating the deployment of advanced product offerings, expanding and enhancing Marpai’s technology platform and deepening market penetration among self-funded employer groups nationwide.

“I continue to invest in Marpai because I believe in what we’re building—smarter healthcare, better outcomes, and a scalable platform that’s disrupting a massive market,” said Damien Lamendola, CEO and Director of Marpai, Inc. “My personal commitment—financial and operational—reflects my deep confidence in our team, our technology, and our ability to execute on a growth strategy that I believe will lead to sustainable profitability. I am all in.”

The offering is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $150 billion TPA sector and $550 billion Pharmacy Benefit Management (“PBM”) industry serving self-funded employer health plans representing over $1.5 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://ir.marpaihealth.com.

About HillCour Investment Fund

HillCour Investment Fund is a private investment vehicle managed by Damien Lamendola, focused on high-growth, technology-driven companies positioned for disruptive market impact.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance,” “may,” “can,” “could”, “will”, “potential”, “should,” “goal” and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the expected use of proceeds and that Mr. Lamendola’s personal financial and operational commitment reflects his deep confidence in the Company’s team, technology and its ability to execute on a growth strategy that it believes will lead to sustainable profitability. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai’s current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai’s current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai’s filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.

SOURCE Marpai

Firm’s sweet spot is backing top technical talent – MIT alumni – with outsized technical depth, a deep sense of urgency and an unmatched ambition to build industry-leading companies

NEW YORK, Oct. 6, 2025 — October 6, 2025 – Sugar Free Capital today announced the launch of its $32 million inaugural fund, investing in (often MIT) technical founders. The firm employs a unique, high conviction strategy, writing lead checks into a concentrated portfolio with high-quality engagement. Founded by proven venture capital investor Sheena Jindal, the fund raised within just six months with commitments from leading institutional investors, and the family offices of technical luminaries, including executives from Nvidia, Citadel, Jane Street, Renaissance Technologies, Crusoe and The Boston Consulting Group.

Sugar Free Capital was founded on two core beliefs: first, that technical founders with a systems engineering mindset will be the CEOs of the next generation of category-defining companies; and second, that high-concentration, conviction-led capital allocation generates outsized returns. The firm focuses on founders who demonstrate outsized technical depth, a deep sense of urgency, and unmatched ambition – and who are building companies designed to scale to $100M+ in revenue.

“The opportunity for (MIT) technical founders has never been greater, and we have been early investors and evangelists of this talent pool for the past decade,” says Jindal. “We operate with focus, allowing us to be the center of gravity for MIT founders. Through our years of cultivating this ecosystem, we support our founders throughout their lifecycle via our network and with mission-critical support, such as go-to-market, engineering talent, and high-quality engagement that allows for long-term partnership.”

Jindal brings more than seven years of institutional venture experience, with prior roles at Bessemer and Comcast Ventures (CV). At CV she was one of the most active Partners, built a top decile track record, and pioneered new investment theses. She served on the boards of OfferUp, Curbio, SevenRooms, Amplemarket, Avibra, and Juno, and was actively involved with other investments, including Nurx and Papa.

A resonant theme across Sugar Free’s founders is technical excellence. Sugar Free consistently invests in teams who are “one of the ten people in the world who could be building this.” This focus creates precision in the firm’s investment philosophy and enables disciplined portfolio construction.

Sugar Free will invest in up to 15 companies per fund, making four to five investments per year. This concentrated approach reflects the firm’s contrarian view that 97% of venture returns come from ~25 companies per year, and Sugar Free’s strategy is to invest in those outliers rather than spread wide. Sugar Free has made four out of 15 investments to date, in category-defining companies building within Physical AI, Gaming, Defense, and AI native-infrastructure. 75% of the portfolio to date is MIT founders, though the firm also backs exceptional technical founders across the U.S.

About Sugar Free Capital
Sugar Free Capital is a high conviction firm investing in (often MIT) Technical Founders who have demonstrated outsized technical depth, have a deep sense of urgency, and an unmatched ambition to build the next category defining companies. The firm leads and invests early, operating with focus – supporting a concentrated portfolio with high-quality engagement. From the earliest stages through scaling and beyond, the firm partners with founders on mission critical support, across go-to-market, engineering talent, and other areas that enable a long-term partnership. SFC is based in New York. Learn more about us here and follow us on LinkedIn and X.

Media Contact:
Tim Turpin
[email protected]

SOURCE Sugar Free Capital

SAN FRANCISCO, Oct. 6, 2025 — Opslyft, a fast-growing technology company that has demonstrated strong traction in India, today announced that it has raised funding from 500 Global and other notable investors. This milestone comes as Opslyft prepares for expansion into the United States, with a strong focus on bringing its AI-powered Cloud Cost Intelligence Platform to American enterprises.

Founded to simplify and optimize cloud and infrastructure operations, Opslyft has built an AI-powered Cloud Cost Intelligence Platform that helps engineering and DevOps teams gain visibility, reduce costs, and automate decision-making. The company has already established early success in India, working with a growing base of customers who are seeing tangible improvements in efficiency, operational agility, and cloud performance.

Now, with the backing of 500 Global, Opslyft is setting its sights on the U.S. market. The company will leverage this investment to scale its go-to-market presence, form partnerships, and double down on AI initiatives that deliver greater customer value. The U.S. remains the world’s largest and most competitive technology market, and Opslyft aims to become a key player by helping businesses unlock new levels of automation and efficiency in their cloud operations.

“Joining the 500 Global portfolio is a major milestone for us,” said Aayush Kumar, Founder and CEO of Opslyft. “We’ve validated our solutions in India and proven that companies want smarter ways to manage cloud costs. This funding will allow us to build a strong U.S. presence while continuing to invest in AI-driven innovation that creates long-term value for our customers.”

Opslyft’s vision is to empower global enterprises to innovate faster by removing cloud cost bottlenecks and optimizing resources through intelligent automation. With this funding, the company is poised to accelerate growth, expand its team in the United States, and establish itself as a category-defining company in cloud cost intelligence.

Media Contact:
Aayush Srivastava
Head of Growth
[email protected]

Logo: https://mma.prnewswire.com/media/2789431/OPSLYFT_Logo.jpg

SOURCE Opslyft

• MediView secures $24M Series A led by GE HealthCare, Mayo Clinic, and Cleveland Clinic to revolutionize image-guided surgery through augmented reality and AI.
• AR-powered “X-ray vision” gives clinicians real-time 3D data insights—fusing CT and live ultrasound for unprecedented precision, safety, and collaboration in surgery.
• FDA-Cleared navigation platform redefines how physicians see and treat inside the body—simplifying procedures and expanding access to less invasive care.
• Funding accelerates commercialization, clinical validation, global expansion, and product development of MediView’s cutting-edge surgical visualization and navigation ecosystem.

CLEVELAND, Oct. 6, 2025 — MediView XR, Inc., a pioneer in augmented reality (AR) surgical navigation, guidance, and image fusion, today announced the close of its $24 million Series A funding round. The round was led by GE HealthCare with investment from Cleveland Clinic, Mayo Clinic, Edge Ventures, the investment arm of Emplify Health, and JobsOhio Growth Capital Fund. The investor syndicate underscores strong confidence from some of the world’s most influential healthcare and technology leaders. 

MediView, a medtech company founded upon Cleveland Clinic-developed intellectual property, has introduced a new FDA-cleared surgical navigation and imaging platform that empowers clinicians to see 3D anatomy through a patient’s skin during medical procedures. Practitioners can interact with 3D patient data and live medical imaging in real time, integrating advanced visualization with precision procedural guidance. This technology represents a paradigm shift in how physicians plan, navigate, and perform minimally invasive procedures, integrating advanced visualization with precision procedural guidance.

“Our mission is to simplify, democratize, and inform medical procedures by giving clinicians intuitive, real-time 3D visualization and guidance tools to aid in their clinical decision making,” said Mina Fahim, MediView CEO. “We are redefining how to understand and navigate the relationship between interventional tools and target anatomy making less invasive procedures more predictable and accessible. Our partnership and collaboration with GE HealthCare, Cleveland Clinic, Mayo Clinic and Emplify Health accelerates our ability to expand clinical and commercial adoption of our innovative solutions towards improving outcomes, enhancing safety, and creating a new standard in interventional care.” 

Accelerating Growth and Leading Innovation 

With this financing, MediView will: 

• Grow commercial and clinical adoption of its AR clinical solutions. 

• Expand industry partnerships with medical imaging, therapeutic devices, and enabling technology collaborators towards broader adoption. 

• Advance clinical validation/publications and regulatory approvals demonstrating clinical, workflow, and economic value. 

• Continue product and advanced development leadership in surgical visualization, navigation, data insights and remote collaboration, expanding utility across multiple clinical specialties. 
• Grow operational capacity to meet increasing demand from healthcare institutions worldwide. 

Solving Long-Standing Challenges in Imaging 

Current medical imaging forces physicians to translate 2D imaging and flat black and white displays into 3D mental maps, putting a cognitive burden on them as they perform procedures. This often leads them to divert their eyes from the patient, disrupting natural hand–eye coordination. MediView’s AR fusion platform replaces this limitation by giving clinicians “X-ray vision”—the ability to see a patient’s internal anatomy through their skin in full 3D context, overlaid directly into their body.  

By fusing 3D CT scans with live ultrasound, MediView enables real-time, interactive visualization of organs, tissue, vasculature, and target anatomy such as tumors. This empowers proceduralists to: 

• Target inconspicuous lesions with accuracy. 

• Reduce cognitive load and improve workflow efficiency. 

• Maintain precision during challenging interventions such as biopsies, tumor ablations, injections and other interventional procedures. 

• Collaborate remotely with colleagues through shared visualization and guidance tools. 

• The result is a head-up, hands-free 3D experience that transforms pre-operative planning and intra-operative navigation—bringing new clarity, ergonomics, and collaboration into interventional procedures. 

“Our collaboration with MediView reflects a shared commitment to integrating advanced imaging with intuitive augmented reality technologies that have the potential to transform precision care,” said Meraj Khan, Chief Marketing Officer, Surgical Innovations, Advanced Visualization Solutions, GE HealthCare. “We’re proud to help lead this funding round and redefine how clinicians visualize anatomy in real-time to enhance procedural guidance and navigation.”

Rapid advancements in AI, paired with the inevitable intersection of AR are set to dramatically transform surgery by reducing time-consuming tasks.  This powerful combination has the potential to significantly streamline crucial medical workflows, including image processing, preoperative planning and post operative processes.  By integrating AI into AR-enhanced medical systems, healthcare providers can look forward to faster, more efficient, and potentially more precise surgical operations.

About MediView 

MediView is a Cleveland, OH based med-tech company working to advance healthcare delivery through intuitive visualization, seamless collaboration, and data-driven insights. MediView’s comprehensive augmented reality platform aims to unlock the full potential of 3D data to transform image-guided medical procedures, making less invasive procedures more accessible.

For media inquiries, please contact:  

Karly Kocik 
Digital Marketing & Events Manager 
MediView 
[email protected] 
(216) 306-1977

SOURCE MediView XR, Inc.